SCN5A Variant D2009E
Summary of observed carriers, functional annotations, and structural context for SCN5A D2009E. Data combine curated literature, international cohorts, and gnomAD observations.
Estimated LQT3 penetrance
4%
0/11 effective observations
Estimated BrS1 penetrance
5%
0/11 effective observations
Total carriers
1
0 BrS1 · 0 LQT3 · 1 unaffected
Variant features alone are equivalent to phenotyping 0 individuals for Brugada syndrome and 0 individuals for LQT3.
In silico predictors
PROVEAN | PolyPhen-2 | BLAST-PSSM | REVEL | Penetrance Density BrS (%) | Penetrance Density LQT3 (%) |
---|---|---|---|---|---|
-0.2 | 0.001 | 0.6 | 0.441 | 2 | 6 |
PROVEAN scores below -2 suggest deleterious impact. REVEL scores above 0.5–0.75 are often interpreted as likely pathogenic. PolyPhen-2 scores above 0.85 are typically pathogenic. Penetrance density summarises neighbouring residue risk (Kroncke et al. 2019).
Reported carrier data
Source | Year | Carriers | Unaffected | LQT3 | BrS1 | Other | Other Disease |
---|---|---|---|---|---|---|---|
Literature, cohort, and gnomAD | – | 1 | 1 | 0 | 0 | – | |
Variant features alone | – | 15 | 15 | 0 | 0 | – | – |
Totals may differ from individual publications due to duplicate patients removed during curation.
Nearby variants
Neighbouring residues within 15 Ångström provide structural context. Variants listed in the right-most column have been observed clinically or in gnomAD.
Neighbour residue | Distance (Å) | Observed variants |
---|---|---|
1994 | 15 | |
1995 | 14 | Y1995X, |
1996 | 14 | S1996N, S1996R, |
1997 | 13 | H1997R, |
1998 | 13 | |
1999 | 12 | |
2000 | 11 | D2000Y, |
2001 | 11 | |
2002 | 10 | A2002T, |
2003 | 9 | D2003N, |
2004 | 8 | F2004V, F2004L, p.F2004dup, F2004I, |
2005 | 8 | P2005L, P2005S, P2005A, |
2006 | 7 | P2006T, p.Pro2006del, P2006A, p.P2006LfsX32, |
2007 | 5 | p.S2007FfsX7, |
2008 | 4 | P2008L, |
2009 | 0 | D2009E, |
2010 | 4 | R2010G, |
2011 | 5 | |
2012 | 7 | R2012H, R2012C |
2013 | 8 | |
2014 | 8 | |
2015 | 9 | |
2016 | 10 | V2016M, V2016L, |